PLP-N inhibitors are a class of chemical compounds that specifically target pyridoxal phosphate-dependent enzyme N (PLP-N), an enzyme that utilizes pyridoxal 5'-phosphate (PLP) as a cofactor to catalyze crucial reactions in amino acid metabolism. PLP-N, like other PLP-dependent enzymes, plays a key role in processes such as transamination, decarboxylation, and racemization, all of which are vital for the transformation of amino acids into their respective metabolites. These reactions are essential for maintaining the balance of amino acids within cells and are necessary for processes like protein synthesis, nitrogen metabolism, and the production of neurotransmitters. By inhibiting PLP-N, these compounds disrupt the enzyme's ability to carry out these critical reactions, leading to alterations in metabolic pathways that depend on the proper processing of amino acids.
The inhibition of PLP-N occurs through mechanisms that involve binding to the enzyme's active site or its pyridoxal phosphate-binding domain, preventing the enzyme from catalyzing its normal reactions with amino acid substrates. This interference has downstream effects on various cellular processes that rely on amino acid metabolism, such as energy production, cellular signaling, and the synthesis of important biomolecules. Researchers use PLP-N inhibitors to explore the specific role of this enzyme in regulating cellular metabolism and to gain a deeper understanding of how disruptions in PLP-dependent enzymatic activity affect broader biochemical networks. By studying the effects of inhibiting PLP-N, scientists can uncover the intricate connections between amino acid transformations and their impact on cellular function, metabolic balance, and overall homeostasis within organisms. These inhibitors are valuable tools for investigating how PLP-dependent enzymes like PLP-N contribute to the complex processes governing cellular growth and metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D inhibits RNA synthesis, potentially impacting the expression of PRL7B1 at the transcriptional level. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide inhibits RNA polymerase and NF-κB, potentially affecting the transcription of PRL7B1 and its regulatory pathways. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases, potentially affecting the transcriptional regulation of PRL7B1 and its associated pathways. | ||||||
Triamcinolone acetonide | 76-25-5 | sc-205872 sc-205872A | 50 mg 250 mg | $56.00 $149.00 | ||
Triamcinolone acetonide is a glucocorticoid receptor agonist, and its modulation of transcriptional activity may impact the expression of PRL7B1. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, potentially impacting the transcription of PRL7B1 and its downstream targets. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor, potentially impacting the epigenetic regulation of PRL7B1 expression. | ||||||
Ellipticine | 519-23-3 | sc-200878 sc-200878A | 10 mg 50 mg | $142.00 $558.00 | 4 | |
Ellipticine is a DNA-intercalating agent, potentially impacting the transcriptional regulation of PRL7B1 and its associated pathways. | ||||||